Shares of Pulmovant rose 1.51% after the Roivant subsidiary reported its Phase 2 trial of mosliciguat hit all pre-specified endpoints in patients with pulmonary hypertension associated with interstitial lung disease, known as PH-ILD.
Results from the PHocus study were presented by Professor Marc Humbert at the European Respiratory Society International Congress 2026.
Mosliciguat is an inhaled soluble guanylate cyclase activator given once daily that targets a key enzyme in the nitric oxide signaling pathway. The drug was tested in 135 patients across 87 sites in 20 countries.
At Week 16, the trial showed a placebo-adjusted reduction in pulmonary vascular resistance of 56.3%, surpassing the primary endpoint. Secondary measures included a placebo-adjusted improvement in six-minute walk distance of 35.2 meters and a 53.2% reduction in NT-proBNP, a biomarker of cardiac strain.
A pre-specified exploratory analysis at Week 24 showed continued gains: six-minute walk distance improved by 52.7 meters, and NT-proBNP fell 75.9% versus placebo.
The drug was well tolerated. Cough, a potential side effect of inhaled therapies, occurred in 12.1% of patients receiving mosliciguat compared with 18.2% on placebo. Adverse events were consistent with the underlying condition.
Pulmovant has now initiated a Phase 3 trial, designated PHrontier, enrolling approximately 375 patients worldwide. Enrollment is underway.
Up to 200,000 patients in the U.S. and Europe live with PH-ILD, a subset of Group 3 pulmonary hypertension, which currently has limited approved treatment options.
